200,000+ products from a single source!
sales@angenechem.com
341028-37-3 | Thiazolium, 4,5-dimethyl-3-(2-oxo-2-phenylethyl)-, chloride
CAS No: 341028-37-3 Catalog No: AG00I6QN MDL No:MFCD09027398
Product Description
Catalog Number:
AG00I6QN
Chemical Name:
Thiazolium, 4,5-dimethyl-3-(2-oxo-2-phenylethyl)-, chloride
CAS Number:
341028-37-3
Molecular Formula:
C13H14ClNOS
Molecular Weight:
267.7744
MDL Number:
MFCD09027398
IUPAC Name:
2-(4,5-dimethyl-1,3-thiazol-3-ium-3-yl)-1-phenylethanone;chloride
InChI:
InChI=1S/C13H14NOS.ClH/c1-10-11(2)16-9-14(10)8-13(15)12-6-4-3-5-7-12;/h3-7,9H,8H2,1-2H3;1H/q+1;/p-1
InChI Key:
MKOMESMZHZNBIZ-UHFFFAOYSA-M
SMILES:
O=C(c1ccccc1)C[n+]1csc(c1C)C.[Cl-]
UNII:
79QS8K2877
Properties
Complexity:
250
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
2
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
267.048g/mol
Formal Charge:
0
Heavy Atom Count:
17
Hydrogen Bond Acceptor Count:
3
Hydrogen Bond Donor Count:
0
Isotope Atom Count:
0
Molecular Weight:
267.771g/mol
Monoisotopic Mass:
267.048g/mol
Rotatable Bond Count:
3
Topological Polar Surface Area:
49.2A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Literature
| Title | Journal |
|---|---|
| Alagebrium in combination with exercise ameliorates age-associated ventricular and vascular stiffness. | Experimental gerontology 20120801 |
| Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice. | Diabetes 20120801 |
| Therapeutic effect of combination of alagebrium (ALT-711) and sildenafil on erectile function in diabetic rats. | International journal of impotence research 20120101 |
| Renoprotective antioxidant effect of alagebrium in experimental diabetes. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20111101 |
| The advanced glycation end product-lowering agent ALT-711 is a low-affinity inhibitor of thiamine diphosphokinase. | Rejuvenation research 20110801 |
| Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. | European journal of heart failure 20110801 |
| Targeted reduction of advanced glycation improves renal function in obesity. | Kidney international 20110701 |
| Does accumulation of advanced glycation end products contribute to the aging phenotype? | The journals of gerontology. Series A, Biological sciences and medical sciences 20100901 |
| Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy. | American journal of physiology. Renal physiology 20100301 |
| Effects of alagebrium, an advanced glycation end-product breaker, in patients with chronic heart failure: study design and baseline characteristics of the BENEFICIAL trial. | European journal of heart failure 20100301 |
| Alagebrium attenuates acute methylglyoxal-induced glucose intolerance in Sprague-Dawley rats. | British journal of pharmacology 20100101 |
| Effect of the age cross-link breaker alagebrium on anterior segment physiology, morphology, and ocular age and rage. | Transactions of the American Ophthalmological Society 20091201 |
| Alagebrium chloride protects the heart against oxidative stress in aging rats. | The journals of gerontology. Series A, Biological sciences and medical sciences 20090601 |
| Letter by Hartog et al. regarding article, 'Advanced glycation end products accumulate in vascular smooth muscle and modify vascular but not ventricular properties in elderly hypertensive canines'. | Circulation 20090317 |
| Advanced glycation end products accumulate in vascular smooth muscle and modify vascular but not ventricular properties in elderly hypertensive canines. | Circulation 20080902 |
| Cardiac inflammation associated with a Western diet is mediated via activation of RAGE by AGEs. | American journal of physiology. Endocrinology and metabolism 20080801 |
| Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the non-enzymatic glycation of apolipoprotein A-I. | Diabetologia 20080601 |
| Therapeutic interruption of advanced glycation in diabetic nephropathy: do all roads lead to Rome? | Annals of the New York Academy of Sciences 20080401 |
| Inhibitors of advanced glycation end-products prevent loss of enteric neuronal nitric oxide synthase in diabetic rats. | Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20080301 |
| Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties. | Diabetologia 20070801 |
| Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes. | Kidney international. Supplement 20070801 |
| Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. | Journal of hypertension 20070301 |
| Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy? | Endocrinology 20070201 |
| Alagebrium: benefit on peripheral arteries. | Journal of cardiac failure 20060901 |
| The breakdown of preformed advanced glycation end products reverses erectile dysfunction in streptozotocin-induced diabetic rats: preventive versus curative treatment. | The journal of sexual medicine 20060301 |
| Prevention and reversal of diabetic nephropathy in db/db mice treated with alagebrium (ALT-711). | American journal of nephrology 20060101 |
| [Progress on the drug therapy for diabetic microangiopathies: AGE inhibitors]. | Nihon rinsho. Japanese journal of clinical medicine 20050601 |
| [Development of therapeutic agents for diabetic neuropathies]. | Nihon rinsho. Japanese journal of clinical medicine 20050601 |
| Advanced glycation end products in diabetes-associated atherosclerosis and renal disease: interventional studies. | Annals of the New York Academy of Sciences 20050601 |
| The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. | Journal of cardiac failure 20050401 |
| The next generation of diabetic nephropathy therapies: an update. | Advances in chronic kidney disease 20050401 |
| [Targeted AGEes and AGEs cross-link in drug discovery: preventing and reversing arterial sclerosis in aging and diabetes]. | Yao xue xue bao = Acta pharmaceutica Sinica 20050101 |
| Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process. | American journal of hypertension 20041201 |
| Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease. | American journal of hypertension 20041201 |
| Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway. | Diabetes 20041101 |
| Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. | Journal of the American Society of Nephrology : JASN 20040801 |
| Crosslink breakers: a new approach to cardiovascular therapy. | Current opinion in cardiology 20040701 |
| Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. | Diabetes 20040701 |
| Cardiovascular and renal effects of a collagen cross-link breaker (ALT 711) in adult and aged spontaneously hypertensive rats. | American journal of hypertension 20040401 |
| Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart. | American journal of physiology. Heart and circulatory physiology 20031201 |
| Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease. | Archives of biochemistry and biophysics 20031101 |
| Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. | Archives of biochemistry and biophysics 20031101 |
| The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20030901 |
| A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. | Circulation research 20030418 |
| [Aminoguanidine and other AGE inhibitors]. | Nihon rinsho. Japanese journal of clinical medicine 20020901 |
| Glucose-mediated cross-linking of collagen in rat tendon and skin. | Clinica chimica acta; international journal of clinical chemistry 20020701 |
| Protein glycation, diabetes, and aging. | Recent progress in hormone research 20010101 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.